Orion Corporation has received favorable pharmacokinetic study results with combined salmeterol-fluticasone formulation of the Easyhaler product family and based on the results Orion is planning to apply for a marketing authorisation for the product in Europe.
Orion currently estimates that the marketing authorisation application could be submitted in Europe during the first half of 2017.
The company has developed a salmeterol-fluticasone formulation combining fluticasone as an anti-inflammatory agent and salmeterol as a long-acting bronchodilator to expand the range of the inhalable Easyhaler drug product family for treatment of asthma and COPD.
“We are extremely satisfied with the favourable results in a challenging development area. Salmeterol-fluticasone combination product will strenghten Orion’s Easyhaler® drug product family that by utilising the same inhaler technlology offers diverse treatment options for treatment of asthma and COPD”, says Reijo Salonen, SVP, Pharmaceutical Research and Development and Chief Medical Officer of Orion Corporation.